High-throughput Genotyping
NGS-based target enrichment methods for higher genotyping efficiency in plant and animal research
Overview
For Molecular Breeding, the Availability and Easy Accessibility of Genomic Resources is a Prerequisite
Although technological advances have provided a range of resources like molecular markers, genetic linkage maps, whole genome sequences, and transcriptomes, agricultural genomics has been facing many challenges.
Celemics provides the solution with our high-throughput genotyping panel.
We have utilized NGS and hybridization-based capture technology, whereby a high number of regions of interest are simultaneously enriched using specifically designed probe, to provide new insights into different agricultural genomics research.
Features & Benefits
NGS-based Target Enrichment
Sequencing Assay
Utilizing NGS-based target enrichment method for higher accuracy and cost-effective experiment compared to conventional methods such as conventional GBS, PCR, and microarray
Comprehensive Analysis with High Accuracy
Perform comprehensive assay of 100 to 10,000 markers with minimized false-negative and false-positives as well as for discovering novel SNPs
Outstanding Performance Regardless of Various Origins
Receive high-quality results enabled by species-specifically designed blocking oligos across all types of origins
Maximized Analytic Efficiency
Benefit from Celemics’ library preparation kits, target capture technology, and multiplexing indices specifically designed for high-throughput genotyping
Comparison with Conventional Technologies
| Advantages | Disadvantage | |
|---|---|---|
| Conventional GBS | 1. Sequencing of multiple samples due to lower amount of data required compared to WGS | 1. Limited biomarkers available due to limited conserved regions, reducing overall resolution 2. Unable to detect SNPs in the restriction sites |
| Microarray |
1. Higher reproducibility than conventional
GBS |
1. Hard to customize new targets (novel biomarkers) 2. Low flexibility to meet various kinds of genotyping |
| PCR | 1. Cost-effective for low number of samples 2. Easy and fast analysis | 1. Limited number of biomarkers to analyze at once 2. Inappropriate for mass-analysis of biomarkers |
| Celemics Target Enrichment | 1. Cost saving : Highly cost-effective when assessing multiple samples
2. Flexible customization : Novel biomarkers can be added or removed 3. Comprehensive analysis : Including novel SNP discovery 4. Exceptional performance : Celemics proprietary blocking oligo design technology 5. Wide compatibility : Compatible with a wide range of sample types |
Related Products
Customized NGS Panel
Customization to Next Level; tailored NGS panel customization and assay optimization
Library Preparation Kit
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
CAS
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
CeleMag Clean-up Bead
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Customization to Next Level; tailored NGS panel customization and assay optimization
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
References
Cancer Research and Treatment
Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Koo DH, Jung M, Kim YH, Jeung HC, Zang DY, Bae WK, Kim H, Kim HS, Lee CK, Kwon WS, Chung HC. Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 2024 Apr 29.
10.4143/crt.2023.1324
Summary | celemics publications
#Oncology
#ctDNA Sample
# AlphaLiquid® 100 Panel
Purpose
Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), HER2, and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).
Result
Genomic alteration landscape in circulating tumor DNA analysis according to the progression-free survival (PFS), overall survival (OS), and EGFR/HER2 immunohistochemical expression (n=15).
Conclusion
A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.
Method
The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.
Related Product
Circulating Tumor DNA Panel for
Colorectal / Lung / Breast Cancer
The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.
| Colorectal Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 100% |
| Freq. 1.0% | 100% | |
| Specificity | 97.9% | |
| Breast Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 94.4% |
| Freq. 1.0% | 100% | |
| Specificity | 96.3% | |
| Lung Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 100% |
| Freq. 1.0% | 100% | |
| Specificity | 100% | |
Cancers
Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel
Hwang J, Bang S, Choi MH, Hong SH, Kim SW, Lee HE, Yang JH, Park US, Choi YJ. Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel. Cancers. 2024 Jan;16(11):2006.
10.3390/cancers16112006
Frontiers in Neurology
Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia
Ammous-Boukhris N, Abdelmaksoud-Dammak R, Ben Ayed-Guerfali D, Guidara S, Jallouli O, Kamoun H, Charfi Triki C, Mokdad-Gargouri R. Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia. Frontiers in Neurology. 2024 May 31;15:1344018.
10.3389/fneur.2024.1344018
Scientific Reports
Sex-specific survival gene mutations are discovered as clinical predictors of clear cell renal cell carcinoma
Hwang J, Lee HE, Han JS, Choi MH, Hong SH, Kim SW, Yang JH, Park U, Jung ES, Choi YJ. Sex-specific survival gene mutations are discovered as clinical predictors of clear cell renal cell carcinoma. Scientific Reports. 2024 Jul 9;14(1):15800.
10.1038/s41598-024-66525-9